phase recoveri balanc
pronounc versu coverag elect
busi mix china exposur recoveri like longer
date spark momentum margin opportun remain
impact pronounc envista report revenu
estim vs dentspli normal
weakest result across coverag consist phase
recoveri classif overli surpris given highli discretionari
busi mix greater china exposur vs med-tech averag
growth includ addit sell day bp
corpor impli organ growth adjust estim net
impact see underli organ growth rel flat
revenu estim attribut
unfavor geograph exposur china discretionari natur
 revenu normal in-lin med-tech also
includ benefit infect prevent sale margin
declin point y/i due unfavor mix heighten invest spark
manufactur capac discuss
look ahead recal envista suspend guidanc earli april manag
state april core sale global admittedli less sever
select spine name could also function geograph
exposur china along recoveri china exit
normal improv end april compani continu
observ improv throughout may assum china return
normal may june respect arriv china
revenu y/i assum slightli conserv recoveri
framework remaind busi declin may
june respect arriv normal organ growth
acceler cost initi envista announc key updat variou near-
compani institut temporari near-term cost reduct
build compani announc earli april
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
includ action compens reduct furlough
aggress manag non-essenti spend
impact appar see major reflect result
connect sever top-line impact
envista amend previous announc cost save program
consist thesi
driver chang reduct headcount well back
offic effici addit compani announc
discontinu pelton treatment unit franchis
revenu carri break-even oper margin see overal
margin accret net neutral ebit
net adjust model incorpor sever impact
reflect lower revenu model margin base
drop-through rate gener consist approach taken across
coverag note may prove conserv given aforement cost initi
updat spark catalyst
receiv european ce mark approv quarter slightli ahead
expect implant made avail select countri
earli june pursu control launch strategi
given implant system like requir greater train
tradit implant updat timelin fda approv
provid continu expect late approv us
contribut model impli revenu major eu
drive bp growth ramp us launch
bp growth
spark showcas practition ormco forum
februari compani continu invest manufactur capac
case request return us eu aus/nz region state
product drove increment revenu quarter
model impli increment revenu may prove
conserv increment revenu would need ramp
per quarter note increment spark revenu
drive bp growth
longer date recoveri like margin pipelin driver intact within
phase recoveri model classifi envista phase recoveri asset given
highli discretionari procedur exposur dental orthodont
gener deferr said commentari initi improv
margin consist thesi see spark key
underli growth driver aid recoveri remain equal-weight
lower price target base ebitda estim
discount
sp segment revenu expos impact geographi
china spain itali franc led acut impact
region farther along recoveri may result less
rel headwind expect term procedur see endodont
procedur lead recoveri follow emerg exist orthodont
case subsequ implant implant core growth track msd
februari premium segment stabil follow leadership disrupt
implant ration initi set anniversari ortho
spark drove bp corpor increment engag remain
high launch strategi remain intact see spark increment
tailwind aid sp recoveri discuss updat model
impli organ growth sp
 dental offic begin reopen world-wide given tailwind
infect prevent busi like consum lead recoveri
follow growth see compani infect prevent busi
grow bp corpor compani invest addit
manufactur capac consist view manag recogn
longer-d recoveri tail larger scale capit envista revenu
higher-pr imag equip fewer new offic open purchas
decis postpon net model organ growth consist
base busi declin modestli off-set point tailwind
infect prevent note manag also suggest distributor inventori
track histor low may lead tailwind upcom quarter
recoveri take shape forecast model
debt coven suspend liquid seem manag earlier week envista
amend credit agreement suspend debt coven includ
minimum liquid posit compani also drew revolv
ad flexibl bring cash posit focus cost
save initi pronounc impact manag
comfort compani manag acut period disrupt
need aris manag highlight addit form liquid measur
could consid short-term facil potenti convert instrument
includ inventori spend compani took measur
proactiv build safeti stock expect reoccur
price target base base case ebitda estim turn
discount see justi given structur lower growth
margin prole howev envista maintain yield vs peer see
envista lead manufactur dental
implant comprehens portfolio
equip consum
compani move past acut
industri disrupt past year
launch sever new product
drive revenu acceler
margin expans initi could
meaning driven improv product mix
cost save program
view descript risk reward theme
recoveri occur rapidli dental
discretionari procedur spark
uptak robust growth acceler
structur result
favor mix combin cost
initi drive bp margin annual
impact sever dental
orthodont procedur recoveri
begin late envista
anniversari channel disrupt
segment ration effort
pressur implant growth spark
contribut growth margin
disrupt persist
recoveri longer anticip
distributor realign ensu volatil
channel new product uptak
mute competit pressur rise
dso preval drive materi price
headwind pt per year save
program fail drive meaning margin
pt market share clear align
market drive pt organ growth
pt market share fully-tap implant
market drive bp organ growth
bp margin expans drive pt ep
china india
view explan region hierarchi
research highest favor quintil
recoveri signic dental
growth faster anticip
mix cost save program drive margin
delay dental procedur
price pressur result dso preval
mute new product uptak implant
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
million except ep
sale
sale
sale
sale
sale
sale
sale
sale
dollar million except per share data
dollar million except per share data
dollar million except per share data
equival
dollar million except per share data
restructur impair charg
chang work capit
oper activ
sale pp
invest activ
net transfer parentco
purchas non-controlling interest
proce debt issuanc
repay debt
proce equiti issuanc net
financ activ
effect exchang rate
